<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IUIS classification of phenocopies of inborn errors of immunity (category X inborn errors of immunity)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IUIS classification of phenocopies of inborn errors of immunity (category X inborn errors of immunity)</h1>
<div class="graphic"><div class="figure"><div class="ttl">IUIS classification of phenocopies of inborn errors of immunity (category X inborn errors of immunity)</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16.6%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect/presumed pathogenesis</td> <td class="subtitle1">Circulating T cells</td> <td class="subtitle1">Circulating B cells</td> <td class="subtitle1">Serum immunoglobulin</td> <td class="subtitle1">Associated features/similar inborn error of immunity</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Associated with somatic mutations</td> </tr> <tr> <td class="indent1">Autoimmune lymphoproliferative syndrome (ALPS-SFAS)</td> <td>Somatic mutation in TNF receptor superfamily member 6 (<em>TNFRSF6</em>)</td> <td>Increased CD4<sup>–</sup>CD8<sup>–</sup> DN alpha-beta T cells</td> <td>Normal but increased numbers of CD5<sup>+</sup> B cells</td> <td>Normal or increased</td> <td>Splenomegaly, lymphadenopathy, autoimmune cytopenias, defective lymphocyte apoptosis; similar to ALPS-FAS (ALPS type Im)</td> </tr> <tr> <td class="indent1" rowspan="2">RAS-associated autoimmune leukoproliferative disease (RALD)</td> <td>Somatic mutation in KRAS proto-oncogene, GTPase (<em>KRAS</em>; GOF)</td> <td>Normal</td> <td>B cell lymphocytes</td> <td>Normal or increased</td> <td>Splenomegaly, lymphadenopathy, autoimmune cytopenias, granulocytosis, monocytosis; ALPS-like</td> </tr> <tr> <td>Somatic mutation in NRAS proto-oncogene, GTPase (<em>NRAS</em>; GOF)</td> <td>Increased CD4<sup>–</sup>CD8<sup>–</sup> DN alpha-beta T cells</td> <td>Lymphocytosis</td> <td>Normal or increased</td> <td>Splenomegaly, lymphadenopathy, autoantibodies; ALPS-like</td> </tr> <tr> <td class="indent1">Cryopyrinopathy (Muckle-Wells/CINCA/NOMID-like syndrome)</td> <td>Somatic mutation in NLR family pyrin domain containing 3 (<em>NLRP2</em>)</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Urticaria-like rash, arthropathy, neurologic signs</td> </tr> <tr> <td class="indent1">Hypereosinophilic syndrome due to somatic mutations in STAT5b</td> <td>Somatic mutation in signal transducer and activation of transcription 5B (<em>STAT5B</em>; GOF)</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Eosinophilia, atopic dermatitis, urticarial rash, diarrhea</td> </tr> <tr> <td class="indent1">VEXAS (vacuoles, E1 enzyme, XL, autoinflammatory, somatic) syndrome</td> <td>Somatic mutation in ubiquitin-like modifier-activating enzyme 1 (<em>UBA1</em>; XL)</td> <td> </td> <td>Reduced</td> <td> </td> <td>Late-onset, treatment-refractory syndrome (fevers, cytopenias, dysplastic bone marrow, interstitial nephritis, chondritis, vasculitis)</td> </tr> <tr> <td class="indent1">TLR8 GOF</td> <td>Somatic mutation in toll-like receptor 8 (<em>TLR8</em>)</td> <td>Mildly increased CD4<sup>+</sup> and CD8<sup>+</sup> T cells, effector/memory subsets; decreased NK cells</td> <td>Normal B cells/subsets; decreased pDCs</td> <td>Normal/low IgG; increased IgM/IgA</td> <td>Severe cytopenias, hepatosplenomegaly, lymphadenopathy, recurrent infections, hypocellular bone marrow, elevated proinflammatory serum cytokines</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Associated with autoantibodies</td> </tr> <tr> <td class="indent1">Chronic mucocutaneous candidiasis</td> <td>Autoantibodies to IL-19 and/or IL-22</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Endocrinopathy, chronic mucocutaneous candidiasis</td> </tr> <tr> <td class="indent1">Adult-onset immunodeficiency with susceptibility to mycobacteria</td> <td>Autoantibodies to IFN-gamma</td> <td>Decreased naïve T cells</td> <td>Normal</td> <td>Normal</td> <td>Mycobacterial, fungal, <em>Salmonella</em>, VZV infections; similar to MSMD or CID</td> </tr> <tr> <td class="indent1">Recurrent skin infection</td> <td>Autoantibodies to IL-6</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Staphylococcal infections; similar to STAT3 deficiency</td> </tr> <tr> <td class="indent1">Pulmonary alveolar proteinosis</td> <td>Autoantibodies to GM-CSF</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Pulmonary alveolar proteinosis, cryptococcal meningitis, disseminated nocardiosis; similar to CSF2RA deficiency</td> </tr> <tr> <td class="indent1">Acquired angioedema</td> <td>Autoantibodies to C1 inhibitor</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Angioedema; similar to C1 inhibitor deficiency (hereditary angioedema)</td> </tr> <tr> <td class="indent1">Atypical hemolytic uremic syndrome</td> <td>Autoantibodies to complement factor H</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Atypical hemolytic uremic syndrome caused by spontaneous activation of the alternative complement pathway</td> </tr> <tr> <td class="indent1">Thymoma with hypogammaglobulinemia (Good syndrome)</td> <td>Autoantibodies to various cytokines</td> <td>Increased CD8<sup>+</sup> T cells</td> <td>No B cells</td> <td>Decreased</td> <td>Invasive bacterial, viral, or opportunistic infections; autoimmunity; PRCA; lichen planus; cytopenia; colitis; chronic diarrhea</td> </tr> <tr> <td class="indent1">Severe COVID-19</td> <td>Autoantibodies to type 1 IFNs (IFN-alpha, IFN-omega)</td> <td> </td> <td> </td> <td> </td> <td>Severe, life-threatening infection with SARS-CoV-2</td> </tr> </tbody></table></div><div class="graphic_lgnd">Total number of conditions in table: 15 (7 due to somatic mutations; 8 due to autoantibodies).</div><div class="graphic_footnotes">IUIS: International Union of Immunological Societies; 
    FAS: Fas cell surface death receptor; 
    TNF: tumor necrosis factor; 
    CD: cluster of differentiation; 
    DN: double negative; 
    GOF: gain of function; 
    CINCA: chronic infantile neurologic cutaneous and articular; 
    NOMID: neonatal-onset multisystem inflammatory disorder; 
    XL: X linked; 
    NK: natural killer; 
    pDC: plasmacytoid dendritic cell; 
    IgG: immunoglobulin G; 
    IgM: immunoglobulin M; 
    IgA: immunoglobulin A; 
    IL: interleukin; 
    IFN: interferon; 
    VZV: varicella zoster virus; 
    MSMD: Mendelian susceptibility to mycobacterial disease; 
    CID: combined immunodeficiency; 
    STAT: signal transducer and activator of transcription; 
    GM-CSF: granulocyte macrophage colony-stimulating factor; 
    CSF2RA: colony-stimulating factor 2 receptor subunit alpha; 
    PRCA: pure red cell aplasia; 
    COVID-19: coronavirus disease 2019; 
    SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</div><div class="graphic_reference">From: Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473. Copyright © 2022 The Authors. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 140093 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
